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ASSOCIATION OF BODY MASS INDEX WITH MORTALITY IN PERITONEAL DIALYSIS PATIENTS: A 
SYSTEMATIC REVIEW AND META-ANALYSIS
Seyed-Foad Ahmadi,1,2 Golara Zahmatkesh,1 Elani Streja,1,3 Rajnish Mehrotra,4 Connie M. Rhee,1 Csaba P. Kovesdy,5,6 
Daniel L. Gillen,2,7,8 Emad Ahmadi,9 Gregg C. Fonarow,10 and Kamyar Kalantar-Zadeh1,2,3,8
Harold Simmons Center for Kidney Disease Research and Epidemiology,1 Division of Nephrology and Hypertension, 
University of California Irvine Medical Center, Orange, California, USA; Department of Population Health and  
Disease Prevention,2 Program in Public Health, University of California Irvine, Irvine, California, USA; Veterans  
Affairs Long Beach Healthcare System,3 Long Beach, California, USA; Kidney Research Institute and Division  
of Nephrology,4 University of Washington, Seattle, Washington, USA; Memphis Veterans Affairs Medical  
Center,5 Memphis, Tennessee, USA; Division of Nephrology,6 University of Tennessee Health Science Center,  
Memphis, Tennessee, USA; Department of Statistics,7 Donald Bren School of Information and Computer  
Sciences, University of California Irvine, Irvine, California, USA; Department of Epidemiology,8 UCLA  
School of Public Health, Los Angeles, California, USA; Department of Radiology,9 Massachusetts  
General Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Division of  
Cardiology,10 UCLA David Geffen School of Medicine, Los Angeles, California, USA
♦ Background: Although higher body mass index (BMI) is associ-
ated with better outcomes in hemodialysis patients, the relation-
ship in peritoneal dialysis (PD) patients is less clear. We aimed to 
synthesize the results from all large and high-quality studies to 
examine whether underweight, overweight, or obesity is associ-
ated with any significantly different risk of death in peritoneal 
dialysis patients.
♦ Methods: We searched MEDLINE, EMBASE, Web of Science, 
CINAHL, and Cochrane CENTRAL, and screened 7,123 retrieved 
studies for inclusion. Two investigators independently selected 
the studies using predefined criteria and assessed each study’s 
quality using the Newcastle-Ottawa Quality Assessment Scale. We 
meta-analyzed the results of the largest studies with no overlap 
in their data sources.
♦ Results: We included 9 studies (n = 156,562) in the system-
atic review and 4 studies in the meta-analyses. When examined 
without stratifying studies by follow-up duration, the results 
of the studies were inconsistent. Hence, we pooled the study 
results stratified based upon their follow-up durations, as sug-
gested by a large study, and observed that being underweight was 
associated with higher 1-year mortality but had no significant 
association with 2- and 3- to 5-year mortalities. In contrast, 
being overweight or obese was associated with lower 1-year 
mortality but it had no significant association with 2-, and 3- to 
5-year mortalities.
♦ Conclusion: Over the short-term, being underweight was asso-
ciated with higher mortality and being overweight or obese was 
associated with lower mortality. The associations of body mass 
with mortality were not significant over the long-term. 
Perit Dial Int 2016; 36(3):315–325 epub ahead of print: 16 Oct 2015
http://dx.doi.org/10.3747/pdi.2015.00052
KEY WORDS: Body mass index; mortality; peritoneal dialy-
sis; meta-analysis; obesity paradox.
Patients with end-stage renal disease undergoing mainte-nance dialysis therapy have a substantially higher risk of 
mortality (1). As in patients undergoing maintenance hemo-
dialysis, cardiovascular disease is the main cause of death in 
patients receiving peritoneal dialysis (PD) (2). Even though in 
the general population obesity is associated with increased risk 
of cardiovascular disease and all-cause mortality, the risk of 
death is lower with increasing body mass (BMI), an indicator 
of obesity, in patients undergoing maintenance hemodialysis 
(3,4). Yet among patients undergoing PD, studies examining 
the association of body mass with mortality have been incon-
sistent; however, some studies have also linked obesity to lower 
mortality in this population (5,6). Given the inconsistent asso-
ciations in studies published to date, we sought to synthesize 
the results from all large and high-quality studies to examine 
whether underweight, overweight, or obesity is associated 
with any significantly different risk of death in PD patients. 
METHODS
SEARCH STRATEGIES
We targeted studies investigating the link between BMI 
and mortality in all chronic kidney disease patients including 
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those receiving PD. We searched MEDLINE (PubMed), Web of 
Science, EMBASE, Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), and Cochrane Central Register of 
Controlled Trials (CENTRAL) up to July 2013 with no limitation 
in study type, language, and geographical area. To search 
PubMed, we used the following search query:
((Renal Insufficiency, Chronic) OR (chronic renal insuf-
ficien*) OR (Kidney Failure, Chronic) OR (chronic renal 
failure) OR (end?stage kidney disease*) OR (end?stage renal 
disease*) OR ESRD OR (chronic kidney disease*) OR (chronic 
renal disease*) OR (Renal Dialysis) OR ((renal OR kidney) AND 
dialys*) OR hemodialys* OR haemodialys* OR ((peritoneal 
OR extracorporeal) AND dialys*) OR Kidney Transplantation 
OR ((kidney OR renal) AND transplant*)) AND ((body mass 
index) OR BMI OR overweight OR obes*) AND (mortality OR 
(death rate*) OR (case fatality rate*) OR survival OR (reverse 
epidemiolog*) OR (obesity AND paradox*))
A similar query was used to search Web of Science, CINAHL, 
and CENTRAL. To search EMBASE, the above search query 
was  tailored to match the searching keywords to EMTREE 
(the EMBASE’s indexing thesaurus). Three f ield experts 
(RM, CPK, KK-Z) were consulted to identify any unidentified 
relevant study.
STUDY SELECTION
After importing the search results into EndNote software 
(Thomson Reuters, New York, NY, USA), we removed duplicated 
records. Two investigators (SFA, GZ), blinded to the study 
authors and journals, independently screened the studies for 
inclusion. The included studies had to describe data from case-
control, cohort, or clinical trial studies to test the association 
of either baseline BMI or change in BMI with all-cause mortality 
in PD patients. Studies with mixed PD and hemodialysis patients 
were not included. Also, studies with fewer than 1,000 PD 
patients were not included as small studies are more likely to be 
influenced by publication (reporting) bias. Any discrepancies 
between the 2 reviewers on study eligibility were resolved by 
discussion and consensus.
DATA ABSTRACTION AND QUALITY ASSESSMENT
We extracted and tabulated the main characteristics and 
findings of the included studies (Table 1). In addition to 
all-cause mortality, we also extracted the results regarding 
technique failure (i.e. transfer to hemodialysis) when avail-
able. The corresponding authors of the studies with incomplete 
data were contacted in order to request further data. To assess 
the quality of the included studies, the same 2 investiga-
tors (SFA, GZ) independently applied the Newcastle-Ottawa 
Assessment Scale (7) assigning a quality score of 0 – 9 to each 
study (Supplementary Table S4). The quality score was based 
on 3 major components: selection of study participants (0 – 4 
points), quality of the adjustment for confounding (0 – 2 
points), and ascertainment of the exposure or outcome of 
interest in case-control studies or cohorts, respectively (0 – 3 
points). The maximum score was 9 points, representing the 
highest methodological quality. Disagreements in the scores 
were resolved by discussion and consensus.
DATA ANALYSIS AND SYNTHESIS
We quantified the inter-rater agreement for selection of 
studies and assessment of quality.
For meta-analyses, we pooled the summary estimates 
of association between BMI and mortality. The summary 
estimates of association between BMI and technique failure 
were not pooled together as technique failure was a post-hoc 
outcome in our study and it was not targeted in our search 
strategies. We assessed statistical heterogeneity using I2 
statistic. Summary statistics with a corresponding I2 ≤ 25% 
were pooled using fixed-effects meta-analysis while summary 
statistics with a corresponding I2 > 25% were pooled using a 
random-effects model. The small number of studies included in 
the meta-analyses prevented us from investigating the risk of 
publication bias using funnel plots and Egger’s tests of asym-
metry. A 95% confidence interval (CI) with no overlap with 
the null effect value (hazard ratio [HR] = 1) was considered 
significant in our study. For statistical procedures, we used 
Stata 12 (StataCorp, College Station, TX, USA).
RESULTS
The retrieved 7,123 citations were screened for inclusion 
based on their titles/abstracts after duplicated records were 
removed. Subsequently, 442 citations were evaluated based 
on their full text article (Figure 1). We finally included 61 
studies of the association of BMI with mortality in chronic 
kidney diseases, and segregated the 8 studies of patients 
who received PD (Table 1) (8–15). An additional study was 
identified through consulting field experts (16). All included 
studies comprised cohorts from pre-existing registry data 
and reported hazard ratios (HRs) from survival regression 
models. The utilized registries included the United States 
Renal Data System (USRDS) (11,13–16), the Australian and 
New Zealand Dialysis and Transplantation Registry (ANZDATA) 
(10,12), the Canadian Organ Replacement Register (CORR) 
(9), and the Brazilian Peritoneal Dialysis Multicenter Study 
(BRAZPD) (8). All included studies had a low risk of bias with 
a quality score range of 7 to 9 out of 9 (Supplementary Table 
S2). Agreement between the 2 investigators was 94% (Kappa: 
0.77) for the study selection and 94% (Kappa: 0.78) for the 
quality assessment.
ASSOCIATION OF BMI WITH ALL-CAUSE MORTALITY
Numerical results are summarized in Supplementary 
Table S5. Badve et al. (12) and Abbott et al. (14) reported 
baseline BMI to have no signif icant association with 
all-cause mortality in PD patients. On the other hand, 
McDonald et al. (10) reported that in comparison with BMI 
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of 20.0 – 24.9 (normal), only BMI ≥ 30.0 (obese) was asso-
ciated with higher mortality while there was no significant 
difference in risk for death among the other groups of BMI. 
In addition, there was no demonstrable association between 
BMI and mortality in the subset of their participants with 
Maori/Pacific Islander racial origins. In contrast, Pliakogiannis 
et al. (9) demonstrated an association only of BMI < 18.5 
(underweight) with a higher mortality compared to BMI of 
18.5 – 24.9 (normal). The trend for better survival in those 
with BMI ≥ 30 (obese) did not reach statistical significance. 
Similarly, Stack and Molony (15) reported that in both sub-
groups of diabetics and non-diabetics, BMI < 20.9 (lowest 
quintile) was associated with significantly higher mortality 
compared with BMI of 23.5 – 26.1 (middle quintile), while 
there was no significant difference in risk for death among 
individuals in other BMI quintiles. Also, Fernandes et al. (8) 
reported that in comparison with BMI of 18.5 – 24.9 (normal), 
BMI of < 18.5 (underweight) was associated with higher 
mortality while BMI of 25.0 – 29.9 (overweight) and BMI 
of ≥ 30.0 (obese) were associated with lower mortality. In 
the largest included study, Mehrotra et al. (16) showed that 
compared with the lowest quintile of BMI, all higher quintiles 
were associated with significantly lower mortality. However, 
if the second quintile (BMI of 21.88 – 24.61) was set as the 
reference group, only the third quintile (BMI of 21.88 – 24.61) 
would be associated with a significantly lower mortality. 
Additionally, Ramkumar et al. (13) reported that BMI ≥ 25.0 
(overweight/obese) was associated with lower all-cause 
and cardiovascular mortality but only in patients with urine 
creatinine of > 0.64 grams/day (g/d) as a surrogate of high 
muscle mass. In contrast, in patients with urine creatinine 
of ≤ 0.64 g/d, all-cause and cardiovascular mortality were 
Figure 1 — Study flow diagram. BMI = body mass index.
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not significantly different for BMI of 18.5 – 24.9 (normal) 
and BMI ≥ 25. 
In the study by Snyder et al. (11), the association of base-
line BMI with 1-, 2-, and 3-year mortality risk were shown to 
be different. The investigators categorized BMI values into 
< 18.5 (underweight), 18.5 – 24.9 (normal; the reference 
group), 25.0 – 29.9 (overweight), and ≥ 30.0 (obese), and 
showed that during the first year of PD, being underweight 
was associated with higher mortality while being overweight 
and obese were associated with lower mortality. Considering 
the first 2 years, being underweight continued to be associated 
with higher mortality and being overweight continued to be 
associated with lower mortality; however, being obese was no 
longer associated with significantly different mortality. In a 
3-year follow-up, being underweight or overweight were no 
longer associated with a differential mortality risk while being 
obese was associated with significantly higher mortality in 
contrast to its 1-year effect. 
Fernandes et al. (8) also assessed the association of weight 
change (in addition to the baseline BMI) with all-cause 
 mortality in PD patients. They observed that a ≥ 3.1% decrease 
in normalized weight was associated with a significantly 
higher mortality. 
META-ANALYSIS OF ALL-CAUSE MORTALITY RESULTS
Four studies were included in meta-analyses (8–11). The 
selected studies used the WHO BMI classification system (17) 
and reported corresponding hazard ratios (HRs) of all-cause 
mortality for underweight, overweight, and obese BMI classes 
at baseline compared with those with normal BMI. The studies 
excluded from meta-analyses had substantial overlap in the 
utilized data sources with the selected studies: Badve et al. 
(12) overlapped with McDonald et al. (10), and the remaining 
4 studies (13–16) overlapped with Snyder et al. (11). 
As Snyder et al. (11) reported differential associations of 
baseline BMI with 1-, 2-, and 3-year mortalities, we stratified 
the meta-analyses based on the follow-up durations: The 
median/mean follow-up durations of the studies by Fernandes 
et al. (8), McDonald et al. (10), and Pliakogiannis et al. (9) 
were 1.08, 1.86, and 4.31 years, respectively. Therefore, the 
HRs from these studies were pooled with the Snyder et al. 
(11) 1-, 2-, and 3-year HRs, respectively (Figures 2 to 4). Our 
meta-analyses showed that being underweight at baseline was 
associated with higher 1-year mortality, being overweight with 
lower 1-year mortality (Figures 2 and 5). Although the pooled 
association of the obese BMI class with 1-year mortality was 
Figure 2 — Forest plots showing the association of baseline BMI classes with 1-year mortality. A, B, and C illustrate the meta-analysis of the 
hazard ratios (HRs) of 1-year mortality in ‘underweight,’ ‘overweight,’ and ‘obese’ BMI classes, respectively, compared with normal BMI. The 3 
BMI cut-points between the ‘underweight,’ ‘normal BMI,’ ‘overweight,’ and ‘obese’ classes were 18.5, 25.0, and 30.0, respectively. The horizontal 
axes are in logarithmic scale. ID = identification; HR = hazard ratio; BMI = body mass index.
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not significant, both meta-analyzed studies (8,11) showed 
that being obese at baseline was associated with lower 1-year 
mortality (Figure 2C). The meta-analyses also showed that 
compared with the normal BMI class, the trend of the asso-
ciation of underweight, overweight, and obese statuses at 
baseline with 2-year and 3- to 5-year mortality risk did not 
reach statistical significance (Figures 3, 4, and 5). 
ASSOCIATION OF BMI WITH TECHNIQUE FAILURE
Four included studies also investigated the association of 
baseline BMI with technique failure, i.e. transfer to hemodialy-
sis (Supplementary Table S6) (10–12,16). Mehrotra et al. (16) 
reported that compared with the lowest BMI quintile, higher 
BMI quintiles were associated with higher risks of technique 
failure. Also, Badve et al. (12) reported that technique failure 
was more likely for a BMI ≥ 30 (obese) compared with a BMI of 
20.0 – 24.9 (normal). In the study by McDonald et al. (10) BMI 
of 25.0 – 29.9 (overweight) and ≥ 30 (obese) were observed 
to be associated with a higher risk of technique failure. 
Similarly, Snyder et al. (11) reported that a BMI of 25.0 – 29.9 
(overweight) and a BMI ≥ 30.0 (obese) were associated with 
higher risks of 1- and 2-year technique failure. Also, a BMI 
≥ 30.0 (obese) was still associated with a higher risk of 3-year 
technique failure.
DISCUSSION
To the best of our knowledge, this is the first meta-analysis 
of published studies evaluating the association of BMI with 
mortality in PD patients. When examined without stratifying 
studies by follow-up duration, the results of the included 
studies were inconsistent. Hence, we pooled study results 
derived from similar follow-up durations and observed that 
being underweight at baseline was associated with a higher 
1-year mortality but had no significant association with 
2- and 3- to 5-year mortalities. Being overweight or obese 
at baseline was associated with lower 1-year mortality but 
had no significant association with 2-, and 3- to 5-year mor-
talities. It is worth noting that although our meta-analysis 
yielded a non-significant pooled association of obesity with 
1-year mortality, the association was significant in both meta-
analyzed studies (Figure 2C). (8,11) This phenomenon rarely 
happens when, in spite of the similar direction of associa-
tion, the magnitude of association is considerably different 
among the pooled results. In this case, the pooled confidence 
Figure 3 — Forest plots showing the association of baseline BMI classes with 2-year mortality. A, B, and C illustrate the meta-analysis of the 
hazard ratios (HRs) of 2-year mortality in ‘underweight,’ ‘overweight,’ and ‘obese’ BMI classes, respectively, compared with normal BMI. The 3 
BMI cut-points between the ‘underweight,’ ‘normal BMI,’ ‘overweight,’ and ‘obese’ classes were 18.5 (in McDonald et al.) or 20.0 (in Snyder et 
al.), 25.0, and 30.0, respectively. The horizontal axes are in logarithmic scale. ID = identification; HR = hazard ratio; BMI = body mass index.
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interval may be disproportionately widened. However, the 
pooled association should be considered significant. Unlike 
BMI–mortality association, technique failure (i.e. transfer to 
hemodialysis) rates were reportedly higher with incremental 
BMI values.
A number of studies have demonstrated a lower risk of death 
in obese individuals in certain populations such as incident 
hemodialysis patients, hospitalized patients, elderly nursing 
home residents, and those with stroke or congestive heart 
failure (5,18–24). This phenomenon is termed the “obesity 
paradox” or “reverse epidemiology” and there are several 
possible explanations for it (5,23). We observed that in PD 
patients, being overweight or obese at baseline was associated 
with lower risk of death over the short term. This finding may 
potentially be due to the contrasting long- and short-term 
consequences of obesity: Although obesity generally increases 
the risk of cardiovascular mortality over the long term, it may 
attenuate the short-term risk of death due to malnutrition, 
inflammation, and protein-energy wasting (25). Notably, one 
of the included studies reported that in PD patients, weight 
loss was associated with a higher risk of death (8). However, 
this study did not examine whether weight loss was due to the 
loss of adipose tissue or muscle mass. Studies of hemodialysis 
patients (26,27) suggest that concurrent weight loss and 
muscle mass gain is associated with greater survival compared 
with concurrent weight gain and muscle mass loss. Also, an 
included study (13) suggested that the protective effect of a 
baseline BMI ≥ 25 may be due to higher muscle mass rather 
than higher adiposity. However, in PD patients, the relative 
influence of muscle mass or adiposity is difficult to evaluate 
because of limited epidemiologic evidence. In hemodialysis 
patients, a few studies have examined whether adiposity and 
muscle mass have differential associations with mortality; 
however, their results have not provided a consistent associa-
tion (5). Also, since BMI can substantially change over time, 
the use of BMI at baseline rather than BMI as a time-varying 
covariate may have contributed to the loss of significant 
associations over longer follow-up durations. For technique 
failure, on the other hand, the association with BMI was rather 
direct and not paradoxical. This is possibly because malnu-
trition does not have a significant bearing on the common 
causes of technique failure such as mechanical and infectious 
complications as well as the inadequate solute clearance 
and/or ultrafiltration (28).
As our results are derived from observational studies, they 
cannot be used to drive weight-management interventions. 
Figure 4 — Forest plots showing the association of baseline BMI classes with 3- to 5-year mortality. A, B, and C illustrate the meta-analysis of 
the hazard ratios (HRs) of 3- to 5-year mortality in ‘underweight,’ ‘overweight,’ and ‘obese’ BMI classes, respectively, compared with normal 
BMI. The 3 BMI cut-points between the ‘underweight,’ ‘normal BMI,’ ‘overweight,’ and ‘obese’ classes were 18.5, 25.0, and 30.0, respectively. 
The horizontal axes are in logarithmic scale. ID = identification; HR = hazard ratio; BMI = body mass index.
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However, in the absence of clinical trials, our findings can 
inform clinical practice by emphasizing that individual patient 
characteristics should influence decision-making regarding 
weight management, for example in obese PD patients with 
short life expectancy, it may not be necessary to advocate 
weight loss, whereas this may potentially be helpful in those 
with longer life expectancy.
In this systematic review, we searched multiple databases 
using sensitive search strategies. Moreover, we only included 
large studies (i.e. those with ≥ 1,000 patients undergoing 
PD) that provided higher accuracy and lower likelihood of 
publication bias. Furthermore, our study selection and quality 
assessment were carried out in duplicate. However, our study 
possesses the inherent limitations of systematic reviews of 
observational studies. Although the included studies repre-
sent the largest and highest-quality observational studies on 
the subject, their results were adjusted for only recognized 
and measured confounders. In addition, the included studies 
were from different geographical areas and they had differ-
ent ranges of BMI values. Moreover, we were not able to run 
formal tests of publication bias due to the limited number 
of included studies in each meta-analysis. Furthermore, we 
used BMI as a surrogate of obesity even though it does not 
provide accurate information about adiposity or body com-
position. Nevertheless, BMI is still used in clinical practice 
to drive weight management and hence our results have 
clinical relevance.
In conclusion, over short-term follow-up, being under-
weight was associated with a higher risk of death and being 
overweight or obese with a lower risk of death. The associations 
were not significant over long-term follow-up. It is plausible 
that, despite its long-term consequences, obesity may in fact 
favorably impact short-term outcomes by attenuating the risk 
of malnutrition.
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